# A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Source: https://onco.cc/trials/nct05329766/  
OnCo record `nct05329766` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Domvanalimab, Quemliclustat, Zimberelimab and Oxaliplatin in advanced solid tumours, run by Arcus Biosciences, Inc., active and no longer recruiting.

## Summary

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies is a phase 2 interventional study registered as NCT05329766 by Arcus Biosciences, Inc., with 332 participants enrolled, started 2022-06-10 and due to reach its primary completion in 2027-01. Interventions recorded: Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin and Oxaliplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05329766
- Phase: 2
- Setting: A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
- Sponsor: Arcus Biosciences, Inc.
- Enrolled: 332

## Sources

- ClinicalTrials.gov NCT05329766: https://clinicaltrials.gov/study/NCT05329766

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Domvanalimab](https://onco.cc/drugs/domvanalimab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Quemliclustat](https://onco.cc/drugs/quemliclustat/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Arcus Biosciences](https://onco.cc/companies/arcus-biosciences/), [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05329766.json